Dexcom Inc Stock Investor Sentiment

DXCM Stock  USD 134.30  0.44  0.33%   
About 56% of all DexCom's investors are looking to take a long position. The analysis of overall sentiment of trading DexCom Inc stock suggests that some investors are interested at this time. DexCom's investor sentiment overview provides quick insight into current market opportunities from investing in DexCom Inc. The current market sentiment, together with DexCom's historical and current headlines, can help investors time the market. In addition, many technical investors use DexCom Inc stock news signals to limit their universe of possible portfolio assets and to time the market correctly.

Panic Vs Confidence

56

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use DexCom's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward DexCom Inc.
DexCom stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of DexCom daily returns and investor perception about the current price of DexCom Inc as well as its diversification or hedging effects on your existing portfolios.

DexCom Historical Sentiment

Although DexCom's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding DexCom, such as negative comments on social media and news outlets, may cause fear in the market and push DexCom's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of DexCom.
  

DexCom Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards DexCom can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

DexCom Inc Historical Investor Sentiment

Investor biases related to DexCom's public news can be used to forecast risks associated with an investment in DexCom. The trend in average sentiment can be used to explain how an investor holding DexCom can time the market purely based on public headlines and social activities around DexCom Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
DexCom's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for DexCom and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average DexCom news discussions. The higher the estimate score, the more favorable the investor's outlook on DexCom.

DexCom Maximum Pain Price across 2024-04-19 Option Contracts

DexCom's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of DexCom close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of DexCom's options.
18 hours ago at finance.yahoo.com         
Reasons to Retain DexCom Stock in Your Portfolio for Now
Yahoo News
a day ago at cnbc.com         
Abbott Labs surprise guidance bump is a major positive for its shareholders
cnbc News
a day ago at benzinga.com         
1000 Invested In DexCom 5 Years Ago Would Be Worth This Much Today
benzinga news
2 days ago at investing.com         
Dexcom executive sells 274k worth of company stock
Investing News at Macroaxis
2 days ago at gurufocus.com         
EVP Strategy and Corporate Dev Matthew Dolan Sells Shares of DexCom Inc
Gurufocus Stories at Macroaxis
3 days ago at zacks.com         
Disposition of 1990 shares by Matthew Dolan of DexCom at 137.81 subject to Rule 16b-3
zacks News
3 days ago at zacks.com         
DexCom Stock Moves -1.16 percent What You Should Know
zacks News
few days ago at investorplace.com         
Disruptive Forces 3 Game-changing Stocks Reshaping the Tech Landscape
sbwire news
few days ago at simplywall.st         
Why Were Not Concerned About DexCom, Inc.s Share Price
Simply Wall St News at Macroaxis
six days ago at investing.com         
Tandem Diabetes shares target raised, Hold rating retained by CFRA
Investing News at Macroaxis
over a week ago at investorplace.com         
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild
sbwire news
over a week ago at investing.com         
Dexcom CEO Kevin Sayer sells shares worth over 6.8 million
Investing News at Macroaxis
over a week ago at massdevice.com         
Dexcom, MD Revolution partner to integrate CGM into remote care platform
news
over a week ago at gurufocus.com         
Insider Sell DexCom Inc President, CEO and Chairman Kevin Sayer Sells 49,633 Shares
Gurufocus Stories at Macroaxis
over a week ago at zacks.com         
Should First Trust Growth Strength ETF Be on Your Investing Radar?
zacks News
Far too much social signal, news, headlines, and media speculation about DexCom that are available to investors today. That information is available publicly through DexCom media outlets and privately through word of mouth or via DexCom internal channels. However, regardless of the origin, that massive amount of DexCom data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of DexCom news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of DexCom relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to DexCom's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive DexCom alpha.

DexCom Performance against NYSE Composite

 Price Growth (%)  
       Timeline  
1
Whats Driving DexCom Incs Surprising 13 percent Stock Rally
03/07/2024
2
RBC Capital starts DexCom with Outperform on growth potential
03/12/2024
3
Disposition of 1003 shares by Matthew Dolan of DexCom at 131.3912 subject to Rule 16b-3
03/15/2024
4
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 430 p.m. Eastern Time
04/02/2024
5
Disposition of 22361 shares by Kevin Sayer of DexCom at 138.7079 subject to Rule 16b-3
04/08/2024
6
Should First Trust Growth Strength ETF Be on Your Investing Radar
04/09/2024
7
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild
04/10/2024
8
Why Were Not Concerned About DexCom, Inc.s Share Price
04/12/2024
9
DexCom Stock Moves -1.16 percent What You Should Know
04/15/2024
10
1000 Invested In DexCom 5 Years Ago Would Be Worth This Much Today
04/17/2024
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:
Check out DexCom Hype Analysis, DexCom Correlation and DexCom Performance.
Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for DexCom Stock analysis

When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Commodity Directory
Find actively traded commodities issued by global exchanges
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.81
Earnings Share
1.31
Revenue Per Share
9.384
Quarterly Revenue Growth
0.269
Return On Assets
0.0641
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.